Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
Department of Ophthalmology and Vision Science, School of Medicine, University of California, Davis, CA, USA.
J Feline Med Surg. 2024 Nov;26(11):1098612X241278413. doi: 10.1177/1098612X241278413.
The aim of this study was to prospectively evaluate in a randomized, triple-masked, placebo-controlled trial, outcomes for kittens with ocular manifestations of infectious upper respiratory disease (IURD) treated with an ophthalmic and oral antibiotic only vs those also treated with famciclovir.
Kittens were stratified into three age (1 to <4, 4 to <8 or 8-12 weeks) and two disease severity ('mild' [total disease score 1-11] or 'severe' [total disease score 12-23]) groups and randomized to receive approximately 5 mg/kg doxycycline either with placebo (group D) or with approximately 90 mg/kg famciclovir (group DF) PO q12h. Caregivers scored clinical signs once daily for 21 days. Ophthalmic examinations and scoring by veterinarians were completed on days 1 and 21. Ophthalmic and clinical resolution were defined as scores of zero for all ocular signs and all ocular and respiratory signs, respectively. Ophthalmic and clinical recovery were defined by absence of active inflammation.
For kittens with mild disease, those in group D were slower than those in group DF to achieve clinical recovery ( = 0.049) and clinical resolution ( = 0.030), but not ophthalmic recovery ( = 0.064) or ophthalmic resolution ( = 0.089). Kittens with mild disease and receiving famciclovir achieved predicted 75% clinical resolution 4-5 days earlier than kittens with mild disease and receiving doxycycline alone, and kittens with severe disease (regardless of treatment group). Significantly fewer kittens in group DF developed corneal disease than in group D ( = 0.016). All five kittens whose clinical signs worsened sufficiently to be removed from the study were in group D.
The addition of famciclovir to standard antibiotic treatment may reduce corneal disease, length of stay and time to adoption for shelters and rescue groups, thereby increasing capacity for care. Early administration of famciclovir in kittens exhibiting mild ocular manifestations of IURD may be preferable to delaying this treatment until the disease progresses to a severe stage.
本研究旨在前瞻性评估眼部表现为传染性上呼吸道疾病(IURD)的小猫,接受眼科和口服抗生素治疗与同时接受泛昔洛韦治疗的结果。
将小猫按年龄(1 至<4 周、4 至<8 周或 8-12 周)和疾病严重程度(“轻度”[总疾病评分 1-11]或“重度”[总疾病评分 12-23])分为三组,并随机接受约 5mg/kg 强力霉素联合安慰剂(D 组)或约 90mg/kg 泛昔洛韦(DF 组)PO q12h。护理人员每天评分一次,共 21 天。在第 1 天和第 21 天,兽医进行眼科检查和评分。眼部和临床缓解定义为所有眼部症状评分均为零,所有眼部和呼吸道症状评分均为零。眼部和临床康复定义为无活动炎症。
对于轻度疾病的小猫,D 组比 DF 组更慢达到临床康复(=0.049)和临床缓解(=0.030),但在眼部康复(=0.064)或眼部缓解(=0.089)方面无差异。接受泛昔洛韦治疗的轻度疾病小猫比单独接受强力霉素治疗的轻度疾病小猫提前 4-5 天达到预测的 75%临床缓解率,且重度疾病(无论治疗组)的小猫也是如此。DF 组发生角膜疾病的小猫明显少于 D 组(=0.016)。所有临床症状恶化到足以被剔除研究的五只小猫都在 D 组。
在标准抗生素治疗中添加泛昔洛韦可能会减少角膜疾病,缩短收容所和救援组织的停留时间和领养时间,从而提高护理能力。在出现 IURD 眼部轻度表现的小猫中,早期给予泛昔洛韦治疗可能优于等到疾病进展到严重阶段才开始治疗。